AR074304A1 - Moduladores heterociclicos de gamma- secretasa - Google Patents

Moduladores heterociclicos de gamma- secretasa

Info

Publication number
AR074304A1
AR074304A1 ARP090104314A ARP090104314A AR074304A1 AR 074304 A1 AR074304 A1 AR 074304A1 AR P090104314 A ARP090104314 A AR P090104314A AR P090104314 A ARP090104314 A AR P090104314A AR 074304 A1 AR074304 A1 AR 074304A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
hydroxy
substituted
cyano
Prior art date
Application number
ARP090104314A
Other languages
English (en)
Inventor
Anja Limberg
Thomas Luebbers
Karlheinz Baumann
Synese Jolidon
Erwin Goetschi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR074304A1 publication Critical patent/AR074304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere al uso de compuestos de la fórmula (1) en la que R1 es un grupo heteroarilo de cinco o seis eslabones, opcionalmente sustituido por uno o dos R'; R' es alquilo inferior, R2 es H, alquilo inferior, alcoxi inferior, hidroxi halógeno o ciano; Z es N, C, O o S; V es N, C(R"), O o S; W es N, C(R"), O o S, Y es N o C; con la condición de que solo uno de Z, V o W puede ser O o S; R" es H, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es C(O)O-R4; L es un enlace, -(CR42)n-, -C(O)NR4-, -C(O)NR4CH2-, o -C(O)-; R4 puede ser el mismo o diferente y es hidrógeno o alquilo inferior; R3 es alquilo inferior, alcoxi inferior, alquilo inferior sustituido por hidroxi, fenilo opcionalmente sustituido por uno o más R"' o es cicloalquilo; R"' es halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es alcoxi inferior o es C(O)O-R4; n es el número 1, 2 o 3; o las sales de adición de ácido farmacéuticamente activas para la fabricación de medicamentos destinados al tratamiento de la enfermedad de Alzheimer, la angiopatía amiloide cerebral, la hemorragia cerebral hereditaria con amiloidosis de tipo Dutch (HCHWA-D), la demencia multi-infarto, la demencia pugilística o el síndrome de Down. Reivindicación 5: Un compuesto de la fórmula (1-A) comprendido en la fórmula (1) de la reivindicación 1 en la que R1 es un grupo heteroarilo de cinco o seis eslabones, opcionalmente sustituido por uno o dos R', elegido entre el grupo de fórmulas (2); R' es alquilo inferior; R2 es hidrógeno, alquilo inferior, alcoxi inferior, hidroxi, halógeno o ciano; Z es N, C, O o S; V es N, C(R''), O o S; W es N, C(R''), O o S; Y es N o C; con la condición de que solo uno de Z, V o W puede ser O o S; R'' es hidrógeno, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es C(O)O-R4; L es -(CR42)n-, -C(O)NR4-, -C(O)NR4CH2-; R4 puede ser el mismo o diferente y es hidrógeno o alquilo inferior; R3 es alquilo inferior, fenilo opcionalmente sustituido por uno o más R"' o es cicloalquilo; R"' es halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es alcoxi inferior o es C(O)O-R4; n es el número 1, 2 o 3; o las sales de adición de ácido farmacéuticamente activas del mismo.
ARP090104314A 2008-11-10 2009-11-09 Moduladores heterociclicos de gamma- secretasa AR074304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168719 2008-11-10

Publications (1)

Publication Number Publication Date
AR074304A1 true AR074304A1 (es) 2011-01-05

Family

ID=41728178

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104314A AR074304A1 (es) 2008-11-10 2009-11-09 Moduladores heterociclicos de gamma- secretasa

Country Status (13)

Country Link
US (1) US8288403B2 (es)
EP (1) EP2355817A1 (es)
JP (1) JP5378532B2 (es)
KR (1) KR101293421B1 (es)
CN (1) CN102209537A (es)
AR (1) AR074304A1 (es)
AU (1) AU2009312856A1 (es)
BR (1) BRPI0921348A2 (es)
CA (1) CA2743196A1 (es)
IL (1) IL212497A0 (es)
MX (1) MX2011004954A (es)
TW (1) TW201021795A (es)
WO (1) WO2010052199A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
CA2784769A1 (en) * 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
US9718805B2 (en) 2013-06-04 2017-08-01 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
NO3004079T3 (es) 2013-06-04 2018-06-16
JP6532646B2 (ja) * 2013-12-06 2019-06-19 ロレアル パウダー状化粧用組成物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
KR101719419B1 (ko) * 2015-08-05 2017-03-23 건국대학교 산학협력단 베타 아밀로이드의 올리고화 및 섬유화 저해능과 함께 신경세포 보호능력을 갖는 신규 알츠하이머병 치료제
WO2017042114A1 (en) * 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Bridged piperidine derivatives
WO2018106646A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US11346848B2 (en) 2017-01-12 2022-05-31 Vib Vzw Γ-secretase stabilizing compound screening assay

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
EP0749488A1 (en) 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
WO1997021704A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002518380A (ja) 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
SE9803773D0 (sv) 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
WO2001005774A1 (fr) 1999-07-15 2001-01-25 Sumitomo Pharmaceuticals Co., Ltd. Composes de cycles heteroaromatiques
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
PL363316A1 (en) * 2000-12-22 2004-11-15 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
MXPA03011706A (es) 2001-06-28 2004-03-19 Smithkline Beecham Plc Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina.
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
ATE511858T1 (de) 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004005262A2 (en) 2002-07-02 2004-01-15 Schering Corporation New neuropeptide y y5 receptor antagonists
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
CA2523126A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
AU2004283814A1 (en) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd. Tetrahydropyridine derivatives
AU2004287849A1 (en) 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
JP2007516989A (ja) * 2003-12-24 2007-06-28 バイエル クロップサイエンス ゲーエムベーハー 植物成長調節
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2005115990A1 (ja) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
EP1802307B1 (en) 2004-10-15 2008-02-27 Glaxo Group Limited Pyrrolidine derivatives as histamine receptors ligands
JP2008521862A (ja) 2004-12-01 2008-06-26 デブジェン エヌブイ イオンチャンネル、特にｋｖファミリーのイオンチャンネルと相互作用する５−カルボキサミド置換チアゾール誘導体
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
DE102005019201A1 (de) 2006-04-19 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007051333A1 (en) 2005-11-02 2007-05-10 Oncalis Ag Triazine beta-secretase inhibitors
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
WO2007058304A1 (ja) 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
US20090270623A1 (en) 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CA2629745A1 (en) 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
JP2009519974A (ja) 2005-12-16 2009-05-21 ジェネンテック・インコーポレーテッド 四環系キナーゼ阻害剤
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US8080669B2 (en) 2006-05-12 2011-12-20 Ab Science Process for the synthesis of 2-aminoxazole compounds
WO2007135970A1 (ja) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. ヘテロ環系－シンナミド誘導体
CN101448793A (zh) * 2006-05-19 2009-06-03 卫材R&D管理有限公司 脲型肉桂酰胺衍生物
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
US20080027001A1 (en) 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP2010518083A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジン誘導体
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CN101675045B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
CA2708151A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
ES2375919T3 (es) 2008-01-11 2012-03-07 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide.
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
BRPI0910021A2 (pt) 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

Also Published As

Publication number Publication date
KR20110083731A (ko) 2011-07-20
TW201021795A (en) 2010-06-16
KR101293421B1 (ko) 2013-08-05
JP2012508211A (ja) 2012-04-05
CA2743196A1 (en) 2010-05-14
JP5378532B2 (ja) 2013-12-25
BRPI0921348A2 (pt) 2019-09-24
MX2011004954A (es) 2011-05-30
US8288403B2 (en) 2012-10-16
AU2009312856A1 (en) 2010-05-14
US20100120874A1 (en) 2010-05-13
WO2010052199A1 (en) 2010-05-14
CN102209537A (zh) 2011-10-05
EP2355817A1 (en) 2011-08-17
IL212497A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
AR074304A1 (es) Moduladores heterociclicos de gamma- secretasa
ECSP13012858A (es) Derivados de piperidina puenteada
AR080083A1 (es) Moduladores de gamma-secretasa
AR109829A1 (es) Derivados de piperidina puenteados
AR070437A1 (es) Moduladores de beta - amiloide
AR080177A1 (es) Derivados de piperidina, un procedimiento para su preparacion, y su uso en medicamentos para el tratamiento de enfermedades mentales asociadas a la deposicion del beta-amiloide en el cerebro.
AR107010A1 (es) Derivados de piperidina puenteados
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR105341A1 (es) Derivados de etinilo como moduladores metabotrópicos del receptor del glutamato
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
AR065280A1 (es) Agentes antiparasitarios
AR110122A1 (es) Fenoxitriazoles
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR105965A1 (es) Derivados de piperidina puenteados
AR058077A1 (es) Derivados de acidos fenoxiaceticos
AR052308A1 (es) Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
SE0502254L (sv) Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
NO20073208L (no) 4-fenylsubstituerte tetrahydrotsokindiner og anvendelse derav til a blokkere gjenopptak av norepinefrin, dopamin og serotonin
ES2528441T3 (es) Hetarilaminonaftiridinas

Legal Events

Date Code Title Description
FB Suspension of granting procedure